8-K filing — Lexeo Therapeutics, Inc. (LXEO)
Filed: 2026-08-12 AccNo: 0001193125-26-345722 Size: 18 MB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Lexeo Therapeutics Q2 EPS $(0.30) Misses $(0.28) Estimate
Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 50 percent increase over losses of $(0.60) per share from
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lexeo Therapeutics Says FDA Grants RMAT Designation To LX2020 Gene Therapy For PKP2-ACM Based On Interim Phase I/II HEROIC-PKP2 Data
Fermi, Delta Air Lines And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures mixed, Dow futures up 100 pts. Fermi Inc (FRMI) shares down 20.4% in pre-market along with other stocks declining.